openPR Logo
Press release

Mitre Medical Corp. announces the initial clinical trial enrollment for beating heart surgical mitral regurgitation (MR) reduction with the Mitral Touch® device.

01-26-2018 03:42 PM CET | Health & Medicine

Press release from: Mitre Medical Corp.

Mitre Medical Corp. announces the initial clinical trial

This less invasive procedure offers an alternative approach to mitigate moderate to severe mitral regurgitation.

Silicon Valley, 01/26/2018 - Mitre Medical Corp. announces the initial enrollment of patients treated with the Mitral Touch epicardial annuloplasty device. The procedures were performed by cardiac surgeons Kestutis Rucinskas, M.D., Ph.D. and Gintaras Kalinauskas, M.D. of Vilnius University Hospital Santaros Klinikos, Cardiac Surgery Center in Vilnius, Lithuania.

The Mitral Touch is an epicardial, less-invasive surgical solution to treat functional mitral regurgitation, facilitate reverse ventricular remodeling and potentially prevent the onset of congestive heart failure. Mitral Touch emulates the standard of care - mitral annuloplasty rings, with the empowering feature of not requiring surgeons to stop the heart and place patients on the Heart-Lung Bypass Machine. The Mitral Touch sits on the outside of the heart, providing annular and sub-annular support for MR reduction. The potential benefits include shorter procedure time, less complications and shorter hospital stays.

"The Mitral Touch holds the promise of a less invasive and safer approach to treat patients with mitral valve regurgitation," says John MacMahon, CEO of Mitre Medical Corp. "The Mitral Touch was designed to empower surgeons to assess MR reduction on a beating heart prior to implantation. In this initial patient series, we can confirm that acutely - indeed it does."

"Mitral valve repair is the treatment of choice for patients with mitral valve regurgitation. Deployment of the Mitral Touch device is an easy and straightforward treatment that unlocks the benefits of valve repair for patients we have been unable to treat with currently available devices," states Kestutis Rucinskas, M.D., Ph.D.

Gintaras Kalinauskas, M.D. adds: "Since the procedure is performed on the beating heart, implantation time of the Mitral Touch device is fast. This paves the way for the treatment of a wider range of patients with mitral regurgitation who, due to their state of health, would be too fragile for a conventional surgery."

The Mitral Touch device is currently not approved by the FDA and is not CE marked.

About Mitre Medical Corp.
Mitre Medical Corp. is a medical device company with headquarters in Silicon Valley. The focus of the company is the development of innovative solutions to treat structural heart disease.

Mitre Medical Corp.
10 Rollins Road
Millbrae, CA 94030

Contact information
John MacMahon, CEO

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Mitre Medical Corp. announces the initial clinical trial enrollment for beating heart surgical mitral regurgitation (MR) reduction with the Mitral Touch® device. here

News-ID: 918779 • Views: 1873

More Releases from Mitre Medical Corp.

Mitre Medical Corp.: Mitre Medical Corp, is proud to be an Exhibitor at the upco …
Silicon Valley, March 29, 2019 – Mitre Medical Corp. announces the participation the STS Workshop on Robotic Cardiac Surgery in Atlanta, Georgia. The course will offer extensive hands-on procedural experience in a state-of-the-art robotics training facility. Specially designed for surgical teams, the event will put participants in a realistic, cardiac robotics simulation environment where they can hone their skills in mitral valve repair, coronary bypass, and other cardiac surgery procedures. “We
Mitre Medical Corp. Clinical Data to be Presented Today at EACTS, Including the …
Silicon Valley, October 18, 2018 – The clinical experience with the first 5 Mitral Touch implants enrolled in the ENRAPT MR Trial will be presented today at the EACTS Conference in Milan, Italy. Prof. Dr. med. Klaus Kallenbach of HaerzZenter Luxembourg will also provide the first formal presentation of the Mitral Touch Sizers, a pair of surgical tools that complement the procedure and provide surgeons with their first tool
Mitre Medical Corp.: Mitre Medical Corp. Strengthens Its Team with New Strategic …
Silicon Valley, April 17, 2018 – Mitre Medical Corp. announces successful recruitment of experienced cardiac surgery business executive Maria Sainz as a Strategic Advisor. Ms. Sainz brings more than two decades of medical device industry experience most recently as President and CEO of CardioKinetix. Notable among prior senior leadership roles, she served as President of Guidant’s Cardiac Surgery Division from 2003 through 2006 and as CEO of Concentric Medical. “We are
Mitre Medical Corp.: Completion of the feasibility phase for the Mitral Touch® …
Silicon Valley, 03/28/2018 – Mitre Medical Corp. announces completion of the feasibility phase of the Study of the Mitral Touch System for the Reduction of Mitral Valve Regurgitation (the EnraptMR Trial). Treatment with the Mitral Touch implant has demonstrated safety and technical success including durability of MR reduction at 30 days. “Validation of durable MR reduction on the beating hearts of these challenging patients is a real milestone for

All 5 Releases

More Releases for Mitral

Transcatheter Mitral Valve Replacement Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Transcatheter Mitral Valve Replacement Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 124 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Click to view the full report TOC, figure and tables:   Mitral valve is located on the
Transcatheter Mitral Valve Repair & Replacement Market - Evolution in Geriatric …
The Transcatheter Mitral Repair and Replacement Market is expected to reach $ 1,878 million (both repair and replacement valves) by 2023, with a CAGR of 30.0% from 2017 to 2023. Mechanical valve segments accounted for the largest share of the entire market in 2016. The mitral valve is a heart valve that sends blood from one chamber of the heart to the left atrium to another valve called the left ventricle.
Global Transcatheter Mitral Valve Repair and Replacement Market 2017-2022
Qyresearchreports include new market research report “Global Transcatheter Mitral Valve Repair and Replacement Market Professional Survey Report 2017” to its huge collection of research reports. The comprehensive report here accumulates different perspectives having a place with the global Transcatheter Mitral Valve Repair and Replacement marketplace which verbalizes the overarching day records and fate exposures with respect to the dynamic powers at play. The prime intention in the examination report is to
Transcatheter Mitral Valve Replacement Sees Promising Growth during 2017-22
A new independent 97 page research with title '2017-2022 Transcatheter Mitral Valve Replacement Report on Global and December Market, Status and Forecast, by Players, Types and Applications’ guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions like United States, EU, Japan, China, India and Southeast Asia and important players/vendors such as Abbott Laboratories, Edwards Lifesciences, Micro
Global Transcatheter Mitral Valve Replacement Sales Market Report 2017
MarketResearchReports.Biz presents this most up-to-date research on "Global Transcatheter Mitral Valve Replacement Sales Market Report 2017" Description This report studies sales (consumption) of Transcatheter Mitral Valve Replacement in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Abbott Laboratories Edwards Lifesciences Micro Interventional Devices Neovasc MitrAssist NaviGate Cardiac Structures Valtech ... Market Segment by Regions, this report splits Global
Global Transcatheter Mitral Valve Replacement Market Research Report 2021
This report on global Transcatheter Mitral Valve Replacement market is a research study that is meant to armor existing and emerging players to gain shares. It does so by presenting a comprehensive analysis of the market in terms of revenue (US$ Mn), and also includes a figurative forecast estimation, both for the global as well as regional markets. The report contains an elaborate executive summary, which includes a snapshot that